Tempus Announces Prospective Psychiatric Study

Tempus Announces Prospective Psychiatric Study

NEWS

April 21, 2020

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced its new prospective, pharmacogenomics study in psychiatry. The observational study aims to demonstrate the need for more transparent and reliable access to public data specific to a patient’s pharmacogenetic results, aiding physician interpretation of complex molecular findings that may increase their patient’s risk of experiencing an adverse drug reaction (ADR) from medications selected to treat their psychiatric condition.

The study launches in conjunction with xG, Tempus’ new whole exome, germline assay designed with custom spike-ins for neurological and psychiatric conditions. Physicians who order Tempus’ xG test receive a molecular report with their patient’s genetic information that may be relevant to their patient’s physiological responses to medications. Additionally, physicians receive supplemental, personalized information related to gene-drug interactions that are relevant to the patient’s molecular results, referencing publicly available sources including FDA labels, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, and peer-reviewed scientific articles.

“Historically, mental health conditions have been difficult to accurately diagnose and effectively treat, even though there are dozens of medications in the market,” said Founder and CEO Eric Lefkofsky. “We are committed to helping usher in clinical decision support for psychiatrists that have long-sought a data-driven approach to treating patients with major depressive disorder and other psychiatric illnesses.”

This observational study, which aims to enroll 10,000 patients over the course of the year, involves the collection of combined clinical and molecular health information for psychiatric patients in the U.S. from multiple academic medical centers and community psychiatry practices. Tempus has built the world’s largest database of clinical and molecular data in oncology, and by leveraging these capabilities, Tempus is well on its way to building an equally large database for psychiatric research.

About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.